Early control of diabetes reduces later complications
NEW YORK A study has found that people with diabetes who control their blood sugar have lower risk of complications such as heart attacks and death even 10 years later.
The study, a follow-up study published online Wednesday in the New England Journal of Medicine, involved 3,277 people who had participated in a previous study of 4,209 newly diagnosed diabetics. The follow-up study tracked the patients for 10 years through clinic visits and then questionnaires.
Within a year of the end of the original study, differences in blood sugar control between a group instructed to take diabetes drugs and a group instructed to restrict diet disappeared. The group that took drugs reduced its risk of heart attack by 15 to 33 percent and its risk of death by 13 to 27 percent, depending on which drug it used.
Generics to drive worldwide pharmaceutical growth
SAN JOSE, Calif. Growth in various sectors of the pharmaceutical industry is expected to come from Brazil, Russia, India and China the so-called B.R.I.C. countries according to a new report by Global Industry Analysts.
In the Asia-Pacific region in particular, government restrictions on healthcare spending and low discretionary spending power among the population is increasing sales of low-cost generic drugs, while China has emerged as a region with potentially vast opportunities for global marketplace majors.
Across various countries, the generic drugs market is seeing rapid growth thanks to the need for drugs that can save lives while remaining cost-effective. This is attracting multinational companies into production and marketing of generic versions of branded drugs. Many consumers in developing countries are gaining access to drugs previously out of bounds for them, though many of the drugs violate patents, according to the report, titled “Pharmaceuticals: A Growing Outlook.”
FDA panel votes in favor of Pfizer’s Fablyn
NEW YORK The benefits of Pfizer’s osteoporosis drug Fablyn outweigh its risks, a Food and Drug Administration panel said, recommending the drug for postmenopausal women in a 9-3 vote Monday.
The advisers on the panel said they could not determine whether deaths among patients using the drug were a statistically significant increase over deaths among those receiving a placebo.
But, they said, the decision was neither a clear rejection of the drug nor a clear endorsement.
Pfizer had maintained that numbers showing an increase in deaths among patients using the drug, known generically as lasofoxifene tartrate, were not statistically significant.